Home LiteratureArticle Details
PMID: 2557897 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II.

Biochemistry ·Vol. 28 ·No. 20 ·1989-10-03 ·Pages 8154-60

Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK

Abstract

The p170 and p180 forms of topoisomerase II have been compared. The concentration dependence of ATP for catalytic activity of the two forms of the enzyme was identical, and each was equally sensitive to novobiocin. Orthovanadate was found to be a potent inhibitor of catalytic activity of both p170 and p180, with an IC50 value of about 2 microM for each. Under standard reaction conditions, relaxation of supercoiled pBR322 by p180 was highly processive, while p170 performed the same reaction in a distributive manner. The optimal concentration of KCl for catalytic activity of p180 was 20-30 mM higher than that for p170. Comparison of their thermal stability showed that p180 was inactivated at twice the rate of p170. Teniposide and merbarone selectively inhibited catalytic activity of p170, requiring concentrations 3-fold and 8-fold lower, respectively, than those required for equivalent inhibition of p180. Similar selectivity for p170 was seen for teniposide-stimulated DNA cleavage or its inhibition by merbarone. Analysis of sites of DNA cleavage indicated a subset of sites that were either preferred or unique for each of the enzymes. A synthetic oligonucleotide representative of p170 sites selectively inhibited the p170 enzyme. Immunoblotting of p170 and p180 from U937 cells at different stages of proliferation showed that p170 levels declined as the cells reached the plateau phase of growth, while p180 levels were low during rapid proliferation and increased as the growth rate slowed. The data indicate that the p170 and p180 forms of topoisomerase II can be distinguished biochemically, pharmacologically, and by differential cellular regulation.

MeSH Terms
Adenosine Triphosphate/metabolism Animals Antineoplastic Agents/pharmacology Catalysis Cells, Cultured DNA/metabolism DNA Topoisomerases, Type II/metabolism Electrophoresis, Polyacrylamide Gel Immunoblotting Molecular Weight Nucleic Acid Conformation Plasmids Topoisomerase II Inhibitors
Chemicals
Antineoplastic Agents Topoisomerase II Inhibitors Adenosine Triphosphate DNA DNA Topoisomerases, Type II
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Drake F H
Department of Molecular Pharmacology, Smith Kline and French Laboratories, King of Prussia, Pennsylvania 19406.
Hofmann G A
Bartus H F
Mattern M R
Crooke S T
Mirabelli C K
Article Info
Journal
Biochemistry
Abbr.
Biochemistry
ISSN
0006-2960
Published
1989-10-03
Pages
8154-60
Language
English
Region
United States
NLM ID
0370623
Subset
IM
Grants
NCI NIH HHS · CA 40884 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]